Stereotaxis (STXS) Stock Price, News & Analysis

Company Overview

Stereotaxis, Inc. develops robotic technologies for the treatment of cardiac arrhythmias and other conditions addressed through minimally invasive endovascular procedures. Its systems are designed to help physicians navigate specialized catheters through the cardiovascular system with computerized control and magnetic guidance, supporting procedures such as electrophysiology studies and catheter ablation.

The company’s portfolio includes the Genesis Robotic Magnetic Navigation system, which uses externally controlled magnetic fields to guide compatible catheters, as well as related workflow, visualization and information-management technologies. Stereotaxis also offers robotic catheter-manipulation and navigation solutions intended to improve procedural control, consistency and physician ergonomics.

Founded in 1990 and headquartered in St. Louis, Missouri, Stereotaxis markets its products to hospitals and medical centers in the United States and internationally. The company’s systems have been installed in healthcare facilities across North America, Europe and other global markets. David Fischell serves as president and chief executive officer.

Key Stats

• Today's Range: $1.29 to $1.37
• 50-Day Range: $1.26 to $1.70
• 52-Week Range: $1.24 to $3.59
• Volume: 598,312 shs
• Average Volume: 481,507 shs
• Market Capitalization: $129.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.50
• Consensus Rating: Buy

Stereotaxis Stock Analysis - MarketRank™

Stereotaxis scored higher than 53% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Stereotaxis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Stereotaxis has a consensus price target of $3.50, representing about 171.3% upside from its current price of $1.29.

Amount of Analyst Coverage

Stereotaxis has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Stereotaxis are expected to grow in the coming year, from ($0.22) to ($0.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Stereotaxis is -5.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Stereotaxis is -5.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Stereotaxis has a P/B Ratio of 9.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.00% of the float of Stereotaxis has been sold short.

Short Interest Ratio / Days to Cover

Stereotaxis has a short interest ratio ("days to cover") of 9.94.

Change versus previous month

Short interest in Stereotaxis has recently decreased by 6.18%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Stereotaxis does not currently pay a dividend.

Dividend Growth

Stereotaxis does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 4 news articles for Stereotaxis this week, compared to 1 article on an average week.

Search Interest

Only 9 people have searched for STXS on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.

MarketBeat Follows

14 people have added Stereotaxis to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Stereotaxis insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.03% of the stock of Stereotaxis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

45.35% of the stock of Stereotaxis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/17/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSEAMERICAN:STXS
• CIK: 1289340
• Web: www.stereotaxis.com
• Phone: (314) 678-6100
• Fax: 314-678-6159
• Employees: 131
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Stereotaxis: $3.50
• High Price Target: $4.00
• Low Price Target: $3.00
• Potential Upside/Downside: +171.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.64 million
• Net Margins: -74.24%
• Pretax Margin: -74.24%
• Return on Equity: -130.84%
• Return on Assets: -29.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.42
• Quick Ratio: 0.95

Sales & Book Value

• Annual Sales: $32.38 million
• Price / Sales: 3.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.14 per share
• Price / Book: 9.21

Miscellaneous

• Outstanding Shares: 100,200,000
• Free Float: 84,140,000
• Market Cap: $129.26 million
• Optionable: Not Optionable
• Beta: 1.43